Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2–inactivated vaccine

2Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Nasopharyngeal immune responses are vital for defense against SARS-CoV-2 infection. Although vaccination via muscle immunization has shown a high efficacy in reducing severity and death in COVID-19 infection, breakthrough infection frequently happens because of mutant variants and incompletely established mucosal immunity, especially in the upper respiratory tract. Here, we performed a single-cell RNA and T-cell receptor repertoire sequencing and delineated a high-resolution transcriptome landscape of nasopharyngeal mucosal immune and epithelial cells in vaccinated persons with breakthrough infection and non-vaccinated persons with natural infection as control. The epithelial cells showed anti-virus gene expression diversity and potentially recruited innate immune cells into the nasopharyngeal mucous of vaccinated patients. Upon infection, they released significant pro-inflammatory cytokines and chemokines by macrophages and monocytes and expressed antigen-presenting relevant genes by dendritic cells. Such immune responses of nasopharyngeal innate immune cells would facilitate the strengthened expression of cytotoxic genes in virus-specific T-cell or B-cell differentiation into antibody-secreting cells at the early stage of breakthrough infection through cell interaction between innate and adaptive immune cells. Notably, these alterations of nasopharyngeal immune cells in breakthrough infection depended on the activated Nuclear factor-κB (NF-κB) and NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) signaling rather than type I interferon responses due to the general reduction in interferon-stimulated gene expression. Our findings suggest that vaccination potentially strengthens innate immune barriers and virus-specific memory immune cell responses, which could be quickly activated to defend against variant breakthrough infection and maintain nasopharyngeal epithelial cell integrity. Thus, this study highlights the necessity of a boost via nasal mucous after intramuscular immunization.

References Powered by Scopus

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

10858Citations
N/AReaders
Get full text

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

2113Citations
N/AReaders
Get full text

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

1870Citations
N/AReaders
Get full text

Cited by Powered by Scopus

KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients

0Citations
N/AReaders
Get full text

Variant-specific local tissue response to SARS-CoV-2 in the nasal mucosa: COVID-19

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

He, X., Cao, Y., Lu, Y., Qi, F., Wang, H., Liao, X., … Zhang, Z. (2023). Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2–inactivated vaccine. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1181121

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

50%

Researcher 3

50%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 3

50%

Pharmacology, Toxicology and Pharmaceut... 1

17%

Engineering 1

17%

Medicine and Dentistry 1

17%

Article Metrics

Tooltip
Mentions
News Mentions: 1
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free